AVEO Pharmaceuticals and AstraZeneca: A Platform for Collaboration
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 83 (Table of Contents)
Published: 1 May-2007
DOI: 10.3833/pdr.v2007.i83.345 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
In the context of the business models of platform technology companies #8211; in particular pharmacogenomics-based companies #8211; this feature discusses the recent deal between AVEO Pharmaceuticals and Schering-Plough to develop and commercialise AV-299, AVEO#8217;s humanised monoclonal antibody...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018